ES2179204T3 - Hidrazinas 2-aminocarbonil-1,2-bis(metilsulfonil)-1-sustituidas antitumorales. - Google Patents

Hidrazinas 2-aminocarbonil-1,2-bis(metilsulfonil)-1-sustituidas antitumorales.

Info

Publication number
ES2179204T3
ES2179204T3 ES96923609T ES96923609T ES2179204T3 ES 2179204 T3 ES2179204 T3 ES 2179204T3 ES 96923609 T ES96923609 T ES 96923609T ES 96923609 T ES96923609 T ES 96923609T ES 2179204 T3 ES2179204 T3 ES 2179204T3
Authority
ES
Spain
Prior art keywords
metilsulfonil
bis
aminocarbonil
hydrazins
antitumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96923609T
Other languages
English (en)
Inventor
Alan C Sartorelli
Krishnamurthy Shyam
Philip G Penketh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yale University
Original Assignee
Yale University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yale University filed Critical Yale University
Application granted granted Critical
Publication of ES2179204T3 publication Critical patent/ES2179204T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/50—Compounds containing any of the groups, X being a hetero atom, Y being any atom
    • C07C311/52—Y being a hetero atom
    • C07C311/54—Y being a hetero atom either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea
    • C07C311/55—Y being a hetero atom either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea having sulfur atoms of the sulfonylurea groups bound to acyclic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

LA PRESENTE INVENCION TRATA DE NUEVAS 2 1,2 BIS(METILSULFONIL) NOCARBONIL SU USO PARA TRATAR TUMORES MALIGNOS. LOS AGENTES SON ESPECIALMENTE UTILES EN EL TRATAMIENTO DE CANCERES ANIMALES Y HUMANOS. DOS AGENTES PREFERIDOS EN ESTA CLASE, CON UN USO ESPECIAL EN EL TRATAMIENTO DE TUMORES, SON LA 1,2 BIS(METILSULFONIL) ,2 RBONILHIDRAZINA. ESTOS AGENTES SE CARACTERIZAN POR LO SIGUIENTE: SON INCAPACES DE SUFRIR INACTIVACION MEDIANTE EL MECANISMO DE DESNITROSACION PROPUESTO PARA LA INACTIVACION DE LA ROETILACION O METILACION Y CARBAMOILACION DE CNU.
ES96923609T 1995-07-05 1996-07-02 Hidrazinas 2-aminocarbonil-1,2-bis(metilsulfonil)-1-sustituidas antitumorales. Expired - Lifetime ES2179204T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/497,931 US5637619A (en) 1995-07-05 1995-07-05 Antitumor 2-aminocarbonyl-1, 2-bis(methylsulfonyl)-1-(substituted)hydrazines

Publications (1)

Publication Number Publication Date
ES2179204T3 true ES2179204T3 (es) 2003-01-16

Family

ID=23978924

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96923609T Expired - Lifetime ES2179204T3 (es) 1995-07-05 1996-07-02 Hidrazinas 2-aminocarbonil-1,2-bis(metilsulfonil)-1-sustituidas antitumorales.

Country Status (15)

Country Link
US (1) US5637619A (es)
EP (1) EP0841912B1 (es)
JP (1) JP3869007B2 (es)
KR (1) KR100372632B1 (es)
CN (2) CN1095828C (es)
AT (1) ATE224708T1 (es)
AU (1) AU713128B2 (es)
BR (1) BR9609620A (es)
CA (1) CA2226331C (es)
DE (1) DE69623969T2 (es)
DK (1) DK0841912T3 (es)
ES (1) ES2179204T3 (es)
PT (1) PT841912E (es)
SI (1) SI0841912T1 (es)
WO (1) WO1997002029A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6040338A (en) * 1997-11-03 2000-03-21 Yale University N,n-bis(sulfonyl)hydrazines useful as antineoplastic agents
KR100578425B1 (ko) * 1998-10-16 2007-01-11 씨제이 주식회사 캐테콜 히드라진 유도체, 이의 제조 방법 및 이를 함유한 약제학적 조성물
US6855695B2 (en) * 2003-06-13 2005-02-15 Vion Pharmaceuticals, Inc. Water-soluble SHPs as novel alkylating agents
US7605137B2 (en) * 2004-03-26 2009-10-20 Vion Pharmaceuticals, Inc. Combination therapy comprising cloretazine
EP1793823B1 (en) * 2004-09-21 2012-08-08 Vion Pharmaceuticals, Inc. Phosphate containing prodrugs of sulfonyl hydrazines as hypoxia-selective antineoplastic agents
WO2016033105A1 (en) * 2014-08-29 2016-03-03 The Board Of Regents Of The University Of Texas System Novel capsazepine analogs for the treatment of cancer and other proliferative diseases
KR102643986B1 (ko) 2017-09-29 2024-03-07 사빅 에스케이 넥슬렌 컴퍼니 피티이 엘티디 신규한 인덴계 전이금속 화합물, 이를 포함하는 전이금속 촉매 조성물, 및 이를 이용한 에틸렌 단독중합체 또는 에틸렌과 α-올레핀의 공중합체의 제조방법
KR102100142B1 (ko) 2017-12-21 2020-04-14 사빅 에스케이 넥슬렌 컴퍼니 피티이 엘티디 금속-리간드 착체, 이를 포함하는 에틸렌계 중합용 촉매 조성물 및 이를 이용한 에틸렌계 중합체의 제조방법
KR102714698B1 (ko) 2019-02-28 2024-10-10 사빅 에스케이 넥슬렌 컴퍼니 피티이 엘티디 신규한 테트라아릴보레이트 화합물, 이를 포함하는 촉매 조성물, 및 이를 이용한 에틸렌 단독중합체 또는 에틸렌과 α-올레핀의 공중합체의 제조방법
KR102888777B1 (ko) 2019-12-30 2025-11-21 사빅 에스케이 넥슬렌 컴퍼니 피티이 엘티디 전자 당김 그룹을 갖는 금속-리간드 착체, 이를 포함하는 에틸렌계 중합체 제조용 촉매 조성물 및 이를 이용한 에틸렌계 중합체의 제조방법
KR20220094138A (ko) 2020-12-28 2022-07-05 사빅 에스케이 넥슬렌 컴퍼니 피티이 엘티디 금속-리간드 착체, 이를 포함하는 에틸렌계 중합체 제조용 촉매 조성물 및 이를 이용한 에틸렌계 중합체의 제조방법
KR20230101717A (ko) 2021-12-29 2023-07-06 사빅 에스케이 넥슬렌 컴퍼니 피티이 엘티디 금속-리간드 착체, 이를 포함하는 에틸렌계 중합체 제조용 촉매 조성물 및 이를 이용한 에틸렌계 중합체의 제조방법
KR20230101716A (ko) 2021-12-29 2023-07-06 사빅 에스케이 넥슬렌 컴퍼니 피티이 엘티디 전이금속 화합물, 이를 포함하는 촉매 조성물 및 이를 이용하는 올레핀 중합체의 제조방법
KR20240049151A (ko) 2022-10-07 2024-04-16 사빅 에스케이 넥슬렌 컴퍼니 피티이 엘티디 전이금속 화합물, 이를 포함하는 촉매 조성물 및 이를 이용하는 올레핀 중합체의 제조방법
KR20250085604A (ko) 2023-12-05 2025-06-12 사빅 에스케이 넥슬렌 컴퍼니 피티이 엘티디 전이금속 화합물, 이를 포함하는 촉매 조성물 및 이를 이용한 올레핀 중합체의 제조방법

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4175200A (en) * 1975-04-11 1979-11-20 Uniroyal, Inc. N,N-Disubstituted sulfonyl hydrazines
US4684747A (en) * 1984-12-20 1987-08-04 Yale University N,N'-bis(sulfonyl)hydrazines having antineoplastic activity
US4849563A (en) * 1986-01-21 1989-07-18 Yale University Novel 1-alkyl-1-arenesulfonyl-2-alkoxycarbonylsulfenylhydrazines having antineoplastic activity
US5214068A (en) * 1989-09-06 1993-05-25 Yale University Sulfonylhydrazines and their use as antineoplastic agents and as antitrypanosomal agents
US5101072A (en) * 1989-09-06 1992-03-31 Yale University Sulfonylhydrazines and their use as antineoplastic agents and as antitrypanosomal agents
US5256820A (en) * 1991-11-08 1993-10-26 Yale University 1-alkyl-2-acyl-1,2-disulfonylhydrazines

Also Published As

Publication number Publication date
CN1191482A (zh) 1998-08-26
CA2226331A1 (en) 1997-01-23
CN1405152A (zh) 2003-03-26
US5637619A (en) 1997-06-10
ATE224708T1 (de) 2002-10-15
JPH11508898A (ja) 1999-08-03
KR19990028733A (ko) 1999-04-15
JP3869007B2 (ja) 2007-01-17
AU1193497A (en) 1997-02-05
CA2226331C (en) 2009-05-26
DE69623969D1 (en) 2002-10-31
DE69623969T2 (de) 2003-05-28
EP0841912A1 (en) 1998-05-20
KR100372632B1 (ko) 2003-05-12
SI0841912T1 (en) 2002-12-31
AU713128B2 (en) 1999-11-25
EP0841912A4 (en) 1998-10-14
MX9800129A (es) 1998-03-31
DK0841912T3 (da) 2002-11-11
CN1176067C (zh) 2004-11-17
HK1050892A1 (en) 2003-07-11
BR9609620A (pt) 1999-12-21
CN1095828C (zh) 2002-12-11
PT841912E (pt) 2003-01-31
WO1997002029A1 (en) 1997-01-23
EP0841912B1 (en) 2002-09-25

Similar Documents

Publication Publication Date Title
ES2179204T3 (es) Hidrazinas 2-aminocarbonil-1,2-bis(metilsulfonil)-1-sustituidas antitumorales.
ES2191152T3 (es) Terapia combinada para el tratamiento de psicosis.
CO4340688A1 (es) Derivados de quinazolina y procedimientos de uso de los mismos, como agentes contra el cancer, en los mamiferos.
DK0954299T3 (da) Thyroxin-analoger uden signifikant hormonal aktivitet til behandling af ondartede tumorer
ES2181298T3 (es) Analogos de tiroxina que poseen una actividad hormonal no significativa para el tratamiento de tumores malignos.
SV2002000376A (es) Compuestos, composiciones farmaceuticas y metodos para inhibir proteina quinasa caso #0091-01-sv
ES2071484T3 (es) Derivados de 2,4-diaminoquinazolinas para aumentar la actividad antitumoral.
NO20014560L (no) Quinasoliner og terapautisk anvendelse derav
DE69830072D1 (de) Radioaktive zusammensetzungen zur behandlung von prostatatumoren
ES2135083T3 (es) Trifeniletilenos para la prevencion y el tratamiento de la osteoporosis.
ES2137554T3 (es) 2-(2-amino-3-metoxifenil)-4-oxo-4h-(1)benzopirano para el tratamiento de desordenes proliferantes.
DE60040981D1 (de) BEHANDLUNG MIT ANTI-ErbB2 ANTIKÖRPERN
MXPA03001645A (es) Composiciones y metodos para el diagnostico y tratamiento de tumores.
PT927150E (pt) Compostos de lipoxina e sua utilizacao no tratamento de doencas proliferativas celulares
AR003119A1 (es) Composicion farmaceutica para tratar infecciones virosicas o inhibir el crecimiento de tumores o canceres que comprenden una mezcla de un n- clorofenilcarbamato o un n- clorofeniltiocarbamato y un n- fosfonoglicina y uso de dicha composicion farmaceutica para la manufactura de un medicamento para tratar infecciones virosicas o inhibir el crecimiento de tumores o canceres
ES2056180T3 (es) Nuevos derivados de 2&#39;-halometiliden, 2&#39;-eteniliden y 2&#39;-etinil citidina.
DE60039730D1 (de) Genetisch manipulierte Herpesviren zur Behandlung von Tumoren
AR002987A1 (es) Composicion farmaceutica para el tratamiento de infecciones virales ocanceres o tumores, composicion de dosis unitaria que la comprende y uso para dicho tratamiento
BR9814419A (pt) &#34;combinação de compostos de benzociclo-heptapiridina e drogas antineopláticas para tratamento de doenças proliferativas&#34;
ATE471309T1 (de) Neuartige retinoide und deren verwendung
ES2135722T3 (es) 1,5-benzodiacepinas 5-heterociclicas moduladoras de la cck o de la gastrina.
PT971710E (pt) Utilizacao de queleritrina e radiacao para terapia de tumores
ES2078904T3 (es) Nuevos derivados de neplanocina.
DK1133296T3 (da) Ny terapeutisk anvendelse af nicergolin
ATE306255T1 (de) 19-nor-vitamin d3 derivate mit calciumspiegel erhöhender wirkung